NIH TETRAMER CORE FACILITY (HIV/AIDS)

NIH 四聚体核心设施（艾滋病毒/艾滋病）

• 批准号: 10376127
• 负责人: JOHN ALTMAN
• 金额: $ 30万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-21 至 2027-03-20
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10376127
• 关键词: AIDS/HIV problem; Communities; Core Facility; Databases; Disease; Immune; Immune response; Major Histocompatibility Complex; Mediating; National Institute of Allergy and Infectious Disease; Peptides; Performance; Prevention; Public Health; Reagent; Research; Research Personnel; Research Support; Technology; Therapeutic Agents; United States National Institutes of Health; biomedical resource; improved; novel therapeutics; programs; repository; research and development; vaccine development

The National Institute of Allergy and Infectious Diseases (NIAID) supports research on the basic understanding of immune responses leading to the development of vaccines and novel therapeutic agents for the prevention and treatment of infectious and immune-mediated diseases, and improvements in public health. This research includes support of various reagent facilities, repositories, and databases that provide resources for biomedical researchers. As a part of the research program to improve our understanding of the progression, prevention, and treatment of infectious and immune-mediated diseases, the NIAID supports the NIH Major Histocompatibility Complex (MHC) Tetramer Core Facility. This facility provides synthesis and distribution of soluble MHC tetramer reagents to the global research community.

美国国家过敏和传染病研究所（NIAID）支持对免疫反应的基本理解的研究，导致疫苗开发和新型治疗剂，以预防和治疗传染性和免疫介导的疾病，并改善公共卫生。这项研究包括对各种试剂设施，存储库和数据库的支持，这些设施为生物医学研究人员提供资源。作为研究计划的一部分，旨在提高我们对传染和免疫介导的疾病的进展，预防和治疗的理解，NIAID支持NIH主要的组织相容性复合物（MHC）Tetramer核心设施。该设施将可溶性MHC四聚体试剂的合成和分布分布到全球研究界。